Corporate Overview

Our name, Alimera, derives loosely from ancient Greek. Its intended meaning is "day of truth,"and it represents a company that stands for honesty, integrity, responsibility, candor and trust.We strive to be approachable. We emphasize responsiveness. We realize that there is no substitute for intelligence as we work toward discovering and delivering new products that add therapeutic value. And above all, we approach our relationships ethically, professionally and with a win-win mindset. To the benefit of end customers, healthcare professionals, our partners and our shareholders, these qualities shape the Alimera culture.

Mission

Alimera Sciences is a new kind of pharmaceutical company that's focused on doing the right thing and knowing the right things to do. We are focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. We approach all interactions with a win/win mindset and the goal of proving that an ethically-driven company can greatly impact value.

Strategic Approach

The team at Alimera Sciences has the expertise to design and run preclinical and clinical trials, the ability to navigate through the new drug application process, the relationships to understand customer needs, as well as the drive to launch new products and optimize product distribution.

Alimera Sciences' approach to fulfill unmet needs
in the ophthalmic market is as follows:

• Develop and bring to market Iluvien for the treatment of DME and to evaluate Iluvien
  for other ophthalmic indications.
• Pursue the development, license or acquisition of rights to potential ophthalmic
  drug delivery technologies and compounds. 
• Operate as an ethically-driven company, recognizing our responsibility to
  others and the importance of having a positive impact on those with
  whom we interact.